
Exelixis is on a Mission to Help Cancer Patients Recover Stronger and Live Longer

About Exelixis
Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work in model system genetics, we established a broad drug discovery and development platform that has served as the foundation for our continued efforts to bring new cancer therapies to patients in need.
Learn More

Exelixis Medical Affairs
Exelixis is an oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new products for difficult-to-treat cancers. Discovery efforts have resulted in four approved products available worldwide. Exelixis continues to invest in expansion of our product pipeline through internal drug discovery and strategic business development opportunities.
Learn More
Follow @ExelixisInc on Twitter or like Exelixis, Inc. on Facebook.
KidneyCAN thanks Exelixis for their generous support for KCRS21 as a Founding Partner.